Attachment 1 - Product information for Mabthera

Supplement 1: Summary of major changes to the 2005 Recommendations for Ancillary and Supportive Care. Complication monitoring updates: Minimum monitoring frequencies during systemic immunosuppressive therapy are suggested and thereafter, referral to existing late effects consensus guidelines is advised (Table 2). ................
................